Meet Ron Varrial, New Member of Social Strategy Team

Digital publishing veteran Ron Varrial brings more than 15 years of experience to the social strategy department at Digitas Health LifeBrands. In the newly created role of Vice President/Director, Managing Editor, Varrial will build and execute content plans for several Digitas Health clients, helping a variety of brands improve and build on their social media platforms and communications to patients. He reports to Michael Leis, SVP, Social Strategy, to continue the agency’s industry-leading commitment to providing its clients with innovative and effective connected health offerings.

Varrial brings a unique perspective to social strategy, having built a content incubator at Newsmax Media – one of the largest political websites in the U.S. – that re-imagined what content marketing means in a news environment. As Digital Content Director, he led SEO and content projects to grow brand awareness and product specific marketing. Varrial previously served as Managing Editor for Metro U.S. Newspaper, where he led the paper’s initial transformation toward a digital-first model, delivering sustained 600% growth of traffic and revenue, and the company’s first month of 1 million unique users.

“Health is a thrilling space to be in right now as it undergoes radical transformation, with brands putting patients at the heart of everything they do,” says Varrial. “I’m enthusiastic about taking the next step in my career as part of the Digitas Health team.”

“We are really excited about what Ron brings to this net-new capability,” says Michael Leis, SVP, Social Strategy. “More than just talking about content marketing, our clients now have a tailored, strategic approach to building content platforms that people really want to use to achieve better health outcomes.”

Throughout his career, Varrial has been responsible for discovering and nurturing talent, mentoring an impressive group of writers and editors who have advanced to some of the top brands in the field, including the Associated Press, Reuters, Philadelphia Daily News,, USA Today, Time Magazine, BuzzFeed, Dow Jones (Wall Street Journal) and more.



This news story originally appeared in PharmaVOICE